Anti-Atherogenic Mechanisms of Drebrin
Drebrin 的抗动脉粥样硬化机制
基本信息
- 批准号:10318175
- 负责人:
- 金额:$ 52.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-16 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Actin-Binding ProteinAngiotensin IIAntiatherogenicApolipoprotein EArterial Fatty StreakArterial InjuryArteriesAtherosclerosisCX3CL1 geneCarotid ArteriesCell LineageCell ProliferationCellsCholesterolCommon carotid arteryCongestive Heart FailureDevelopmentDiseaseDown-RegulationDynaminEndocytosisEnzymesExhibitsFoam CellsFractalkineGKLF proteinGSTM1 geneGenerationsGenesGlutathione S-TransferaseGoalsHumanIn VitroInflammatoryKnock-inKnowledgeLeadMass Spectrum AnalysisMediatingMedicalMemoryMetabolismMicrofilamentsMissionMolecularMorbidity - disease rateMusMyocardial InfarctionNADPH Oxidase 1NeuronsNuclearNuclear TranslocationPhagocytesPhenotypePlant RootsPrevalenceProcessProductionProteinsPublic HealthReactive Oxygen SpeciesResearchRoleSignal TransductionSmooth Muscle MyocytesStrokeTestingUnited States National Institutes of HealthVascular Smooth Muscleascending aortaatherogenesisburden of illnesscell motilitycongeniccytokinedisabilitydrebrinsin vivomacrophagemortalitynovel therapeutic interventionoxidized low density lipoproteinresponsetranscription factortransdifferentiationvascular inflammationvascular injurywestern diet
项目摘要
We discovered that the actin-binding protein, Drebrin, is abundantly expressed in smooth muscle cells (SMCs)
and is up-regulated in response to arterial injury in mice and to atherosclerosis in humans. Comparing WT
with Dbn-/+ mice, we found that Drebrin inhibits SMC migration and proliferation, both in vitro and in vivo,
through stabilization of actin filaments. In studies with SMC-specific Dbn-/- (SMC-Dbn-/-) mice, we found that
SMC Drebrin limits angiotensin II-induced remodeling of the ascending aorta, in a manner that correlates with
down-regulation of NADPH oxidase 1 (NOX1), decreased SMC reactive oxygen species (ROS) production and
reduced vascular inflammation. Thus, Drebrin constrains not only the migratory/proliferative SMC phenotype
but also the pro-inflammatory SMC phenotype evoked by vascular injury and angiotensin II. Congruently, we
found that atherosclerosis is greater in SMC-Dbn-/-/Ldlr-/- than in congenic SMC-Dbn+/+/Ldlr-/- mice. Because
SMC Drebrin negatively regulates atherosclerosis, our goals are to determine the mechanisms by which
Drebrin regulates SMC pro-inflammatory signaling and whether enhanced SMC expression of Drebrin can
inhibit atherogenesis. To this end, we performed SILAC/mass spectrometry studies on Dbn-/- and congenic
WT SMCs. We found that whereas in Dbn-/- SMCs the ROS-defensive enzyme Glutathione-S-transferase µ1
(GSTM1) is down-regulated, the pro-inflammatory cytokine CX3CL1 (fractalkine) is up-regulated: thus we will
investigate the role of these proteins in mediating the phenotype of Dbn-/- SMCs. Because endocytosis of
NOX1 regulates ROS generation and activation of pro-inflammatory NFκB signaling and Drebrin has been
shown to inhibit endocytosis, we will investigate whether Drebrin inhibits NOX1-mediated ROS generation by
inhibiting endocytosis. A major focus of our studies will be pro-atherogenic SMC-derived foam cells, which
SMC lineage tracing studies have shown, comprise ~40% of foam cells in atherosclerotic lesions. Our
Preliminary Studies show that, compared with cognate Dbnflox/flox SMCs, Dbn-/- SMCs induced to
transdifferentiate with cholesterol loading exhibited increased expression of the macrophage marker, CD68,
and Kruppel-like factor 4 (KLF4), a transcription factor required for SMC-to-foam cell transdifferentiation. By
grafting common carotid arteries from Dbnflox/flox and SMC-Dbn-/- mice into carotid arteries of congenic Apoe-/-
mice, we also show that Drebrin deficiency augments transdifferentiation of SMCs to CD68+ cells in vivo. We
will test the hypothesis that Drebrin inhibits atherogenesis by limiting SMC transdifferentiation into foam cells.
To do so, we will establish whether Drebrin inhibits SMC-to-foam cell transdifferentiation and associated pro-
inflammatory signaling, both in vitro and in vivo; determine if Drebrin inhibits SMC transdifferentiation through
ROS-dependent mechanisms; and define the roles of GSTM1 and CX3CL1 in mediating Drebrin’s inhibitory
effects on SMC transdifferentiation and pro-inflammatory signaling.
我们发现,肌动蛋白结合蛋白Dreplastin在平滑肌细胞(SMC)中大量表达
并且在小鼠中响应动脉损伤和在人类中响应动脉粥样硬化而上调。比较WT
在Dbn-/+小鼠中,我们发现Dreplatin在体外和体内均抑制SMC迁移和增殖,
通过稳定肌动蛋白丝。在SMC特异性Dbn-/-(SMC-Dbn-/-)小鼠的研究中,我们发现,
平滑肌细胞舒张期限制血管紧张素II诱导的升主动脉重塑,
下调NADPH氧化酶1(NOX 1),减少SMC活性氧(ROS)的产生,
减少血管炎症。因此,Dreplatin不仅限制了SMC的迁移/增殖表型,
还包括血管损伤和血管紧张素II引起的促炎性SMC表型。一致地,我们
发现SMC-Dbn-/-/Ldlr-/-小鼠的动脉粥样硬化程度高于同类SMC-Dbn+/+/Ldlr-/-小鼠。因为
平滑肌细胞负调节动脉粥样硬化,我们的目标是确定其机制,
DREBELINE调节SMC促炎信号传导,以及DREBELINE增强SMC表达是否能
抑制动脉粥样硬化形成。为此,我们对Dbn-/-和同源基因进行了SILAC/质谱研究。
WT SMC。我们发现,在Dbn-/-SMC中,ROS防御酶谷胱甘肽-S-转移酶μ1
(GSTM 1)下调,促炎细胞因子CX 3CL 1(fractalkine)上调:因此,我们将
研究这些蛋白在介导Dbn-/-SMC表型中的作用。因为内吞作用
NOX 1调节ROS的产生和促炎性NFκB信号的激活,
显示抑制内吞作用,我们将研究是否drepletin抑制NOX 1介导的ROS的产生,
抑制内吞作用。我们研究的一个主要焦点将是促动脉粥样硬化SMC衍生的泡沫细胞,
SMC谱系追踪研究表明,动脉粥样硬化病变中约40%为泡沫细胞。我们
初步研究表明,与同源Dbnflox/flox SMCs相比,Dbn-/- SMCs被诱导为
胆固醇负荷的转分化表现出巨噬细胞标志物,CD 68,
和Kruppel样因子4(KLF 4),一种SMC向泡沫细胞转分化所需的转录因子。通过
将Dbnflox/flox和SMC-Dbn-/-小鼠颈总动脉移植到同种Apoe-/-小鼠颈总动脉中,
在小鼠中,我们还表明Drexylase缺陷增强了SMC向体内CD 68+细胞的转分化。我们
将检验Dreplasty通过限制SMC转分化为泡沫细胞来抑制动脉粥样硬化形成的假设。
为了做到这一点,我们将确定Dredrone是否抑制SMC向泡沫细胞的转分化和相关的促分化因子。
炎症信号,在体外和体内;确定是否dreplastin抑制SMC转分化,通过
ROS依赖性机制;并定义GSTM 1和CX 3CL 1在介导Dreplasma抑制性细胞凋亡中的作用。
对SMC转分化和促炎信号传导的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEIL J. FREEDMAN其他文献
NEIL J. FREEDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEIL J. FREEDMAN', 18)}}的其他基金
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis
小核仁 RNA 加剧动脉粥样硬化的机制
- 批准号:
10502380 - 财政年份:2022
- 资助金额:
$ 52.33万 - 项目类别:
Mechanisms by which Small Nucleolar RNAs Exacerbate Atherosclerosis
小核仁 RNA 加剧动脉粥样硬化的机制
- 批准号:
10670399 - 财政年份:2022
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20
去泛素酶 USP20 对血管炎症信号的调节
- 批准号:
9765984 - 财政年份:2019
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20
去泛素酶 USP20 对血管炎症信号的调节
- 批准号:
9893026 - 财政年份:2019
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20
去泛素酶 USP20 对血管炎症信号的调节
- 批准号:
10349573 - 财政年份:2019
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of Vascular Inflammatory Signaling by the Deubiquitinase USP20
去泛素酶 USP20 对血管炎症信号的调节
- 批准号:
10112295 - 财政年份:2019
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20
去泛素酶 USP20 对 B-arrestin2 促动脉粥样硬化活性的调节
- 批准号:
8797106 - 财政年份:2014
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of B-arrestin2's pro-atherogenic activity by the deubiquitinase USP20
去泛素酶 USP20 对 B-arrestin2 促动脉粥样硬化活性的调节
- 批准号:
8639259 - 财政年份:2014
- 资助金额:
$ 52.33万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 52.33万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 52.33万 - 项目类别:
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10707997 - 财政年份:2022
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2022
- 资助金额:
$ 52.33万 - 项目类别:
Discovery Grants Program - Individual
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10555926 - 财政年份:2022
- 资助金额:
$ 52.33万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2021
- 资助金额:
$ 52.33万 - 项目类别:
Discovery Grants Program - Individual
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 52.33万 - 项目类别:
Operating Grants
Intratubular Angiotensin II and AT1a Receptors in The Proximal Tubules: Roles in Hypertension and Kidney Injury
近曲小管中的管内血管紧张素 II 和 AT1a 受体:在高血压和肾损伤中的作用
- 批准号:
10164776 - 财政年份:2020
- 资助金额:
$ 52.33万 - 项目类别:
Novel Roles of Mitochondrial Angiotensin II in The Proximal Tubule of The Kidney
线粒体血管紧张素 II 在肾近端小管中的新作用
- 批准号:
10251271 - 财政年份:2020
- 资助金额:
$ 52.33万 - 项目类别:
Protection and organ injury by angiotensin II treatment for septic shock
血管紧张素II治疗感染性休克的保护作用和器官损伤
- 批准号:
20K09284 - 财政年份:2020
- 资助金额:
$ 52.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




